Navigation Links
Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
Date:9/16/2010

KALAMAZOO, Mich., Sept. 16 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC), www.msdrx.com, will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010.  The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat.  The research was conducted in tissue cultures and mice.

Numerous scientific studies have shown that the amount of brown adipose tissue (commonly known as "brown fat") in the human body is an important factor in determining if calories are burned as energy or stored as fat. 

"Lean people have more brown fat than individuals who are obese," said Jerry Colca, president and chief scientific officer of MSDC.  "The amount of brown fat in the body decreases as an individual ages, particularly in men. If a person had more brown fat, that individual would be better able to lose weight."  

"Our clinical candidates (including MSDC-0160) promote the proliferation of brown fat tissue from stem cells through cellular differentiation," said Rolf Kletzien, senior MSDC author on the study. 

"The ability of our clinical candidates to activate a novel biochemical pathway may provide additional insight and understanding into the mechanism by which they lower blood glucose in human patients without causing weight gain," added Kletzien.

Pharmaceuticals that impact a human's ability to produce brown fat may provide a new means to treat diseases related to excess body weight and cardiometabolic syndrome.

MSDC is a drug development company that is creating and testing a series of pharmaceutical candidates designed to treat type 2 diabetes more effectively without the side effects of current therapies.  

An MSDC Phase 2a clinical trial of MSDC-0160 demonstrated that it improves insulin sensitivity and lowers blood glucose levels in humans without the side effects of the current market-leading diabetes medicines. The compound also demonstrated significant improvements in other important metabolic disease risk factors including blood pressure and lipids.  

About Metabolic Solutions Development Company:Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes. This new approach seeks to improve the efficacy of treatment by freeing patients from the adverse side effects of current treatments, including edema and weight gain.

The company's scientific strategy is built on a historical understanding of insulin-sensitizers and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that the result will be a new generation of superior, safer drug therapies.CONTACT:Nick WasmillerSeyferthPR1-800-435-9539wasmiller@seyferthpr.com
'/>"/>

SOURCE Metabolic Solutions Development Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
2. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
3. Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence
4. Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28
5. Reportlinker Adds Metabolic Endocrinology Hypocalcemia
6. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
7. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
8. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
9. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
10. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
11. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):